GlobeNewswire by notified

Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign

Share

Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign

CAMBRIDGE, England, 1 November 2023 - Jonathan Milner, the founder and one of the largest investors in Abcam plc (“Abcam” or the “Company”) (NYSE: ABCM) with ownership of 6.16% of the Company, today issued the following statement in relation to the proposed acquisition of Abcam by Danaher Corporation (NYSE: DHR) or its affiliates (“Danaher”).

“After extensive feedback from the majority of Abcam’s shareholders, I have today decided to suspend my “Vote AGAINST” campaign. It has become clear that a significant majority intend to support Danaher's acquisition of Abcam and I respect this decision and will not stand in the way of the deal.

Although this outcome is not what I envisioned, I accept the result and wish Abcam and Danaher all the best for their future. My sincere gratitude goes to everyone who supported my campaign over the last few months, especially to my shadow Board nominees: your bravery and loyalty have been deeply appreciated. A special thanks also goes to my team of advisors who, acting with integrity and honesty, ensured every shareholder's voice was heard.

Since the start of my campaign, Abcam’s share price increased significantly and, despite the final outcome, I sincerely believe that our campaign has shown that it is possible to stand up to, and call out, an ineffective Board and Management who displayed disregard for the interests of shareholders. It also drew attention to key metrics, governance issues, and the performance of Executive Directors. It is disappointing that, confronted with these facts, Abcam's Board and leadership team decided to simply put the Company up for sale and accept a subpar offer, at the expense of loyal and long-term shareholders. I hope that my actions will inspire shareholders in other companies to hold their Boards to account.

I extend my heartfelt best wishes to the dedicated staff and loyal customers of Abcam. May they find continued success under the new ownership of Danaher.”

Ends

Jonathan Milner
https://abcamfocus.com/

Investor contact

Alliance Advisors (Europe)
T: +44 7733 265 198 / E: focusabcam@allianceadvisors.com
Michael Roper

Alliance Advisors (US)
T: +1 917 414 4766
Thomas Ball

Peel Hunt LLP
T: +44 (0) 20 7418 8900
Christopher Golden / James Steel
Sohail Akbar / Jock Maxwell Macdonald

International PR advisers

ICR Consilium (Europe)
T: +44 (0)20 3709 5700 / E: focusabcam@consilium-comms.com
Mary-Jane Elliott / Matthew Neal / Davide Salvi

ICR (US)
T: +1 646 677 1811 / E: FocusAbcam@icrinc.com
Dan McDermott

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Correction: Announcement of drawings (CK95) - Nykredit Realkredit A/S28.11.2023 15:01:23 CET | Press release

To Nasdaq Copenhagen Announcement of drawings (CK95) Pursuant to s 24 Danish Capital Markets Act, Nykredit Realkredit A/S hereby publishes drawings data as at 24 November 2023. Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/en-gb/investor-relations/. For further information about data format and contents, please refer to the Nasdaq website. Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21. Yours sincerely Nykredit Realkredit A/S Attachments Announcement of drawings Nykredit Realkredit A_S - 28-11-2023kfdata

Korrektion: Udtrækningsmeddelelse (CK95) - Nykredit Realkredit A/S28.11.2023 15:01:23 CET | pressemeddelelse

Til Nasdaq Copenhagen Udtrækningsmeddelelse (CK95) I medfør af kapitalmarkedsloven § 24 offentliggør Nykredit Realkredit A/S hermed meddelelse om udtrækninger pr. den 24. november 2023. Oplysningerne vil endvidere på sædvanlig måde blive formidlet via Nasdaq Copenhagen. Oplysningerne findes også i excel-format i Nykredits obligationsdatabase på https://www.nykredit.com/en-gb/investor-relations/. For yderligere informationer om dataformat og indhold henvises til Nasdaqs hjemmeside. Spørgsmål kan rettes til head of investor relations Morten Bækmand Nielsen på tlf. 44 55 15 21. Med venlig hilsen Nykredit Realkredit A/S Vedhæftede filer Udtrækningsmeddelelse Nykredit Realkredit A_S - 28-11-2023kfdata

Philips launches ultra lightweight and flexible MR Smart Fit coils to improve radiology productivity and diagnostic confidence at #RSNA2328.11.2023 15:00:00 CET | Press release

November 28, 2023 Amsterdam, the Netherlands and Chicago, USA – RoyalPhilips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today launched three new fit for purpose MR Smart Fit coils at #RSNA23. RF coils are an essential part of every MRI scan. The new ultra-light weight coils provide exceptional flexibility, significant reduction in patient setup time and optimization with Philips’ SmartSpeed AI solution, which allows for better image quality resolution and improved diagnostic confidence for healthcare providers. “Our new Smart Fit coils are an integral part of our patient-centric workflows in MR, with a focus on raising productivity and simplifying workflow,” said Ruud Zwerink, General Manager Magnetic Resonance at Philips. “They combine with our advanced AI-powered software that reduces scanning time and dramatically cuts the number of steps needed to complete an exam. These newly designed coils will help to speed up MR exam process, improving both efficiency and the

Ledende medarbejders transaktioner28.11.2023 14:58:15 CET | pressemeddelelse

Selskabsmeddelelse Nr. 7/2023 København, 28. november 2023 Ledende medarbejders transaktioner Bestyrelsen i Conferize A/S er i dag blevet bekendt med, at 7 investorer har købt 40,26 pct. af selskabets eksisterende aktier fra selskabets 2 hovedaktionærer til en samlet pris på ca. 0,8 mio. kr. – svarende til en pris på 0,01 kr. pr. aktie. Direktør Nicolai Bille Krogh har solgt aktier i Conferize A/S. NAVN:7DREAMS ApSÅRSAG:Nærtstående til Nicolai Bille Krogh, DirektørUDSTEDER:Conferize A/SFONDSKODE:DK0060816148BETEGNELSE:AktierTRANSAKTION:SalgHANDELSDATO:28.11.2023MARKED:Nasdaq First North Growth MarketANTAL STK:40.078.446SALGSSUM DKK:400.784,46 Herudover har Rothausen Development 2016 ApS ejet og kontrolleret af direktør i Suubz ApS, datterselskab i Conferize A/S, solgt aktier i Conferize A/S NAVN:Rothausen Development 2016 ApSÅRSAG:Nærtstående til Claus Andersen, Direktør i datterselskab Suubz ApSUDSTEDER:Conferize A/SFONDSKODE:DK0060816148BETEGNELSE:AktierTRANSAKTION:SalgHANDELSDATO:28

2024 Financial Calendar28.11.2023 14:56:32 CET | Press release

28 November 2023 News Release Pharma Equity Group 2024 Financial Calendar ​March 4Deadline for shareholder proposals - Annual General meeting​ ​March 20 ​Annual Report 2023​ April 16Annual General Meeting​ May 16Interim Report – for the three-month period ended March 31, 2024​ August 16Interim Report – for the six-month period ended June 30, 2024​ November 15Interim Report – for the nine-month period ended September 30, 2024 ​ Contact person – Investor Relations On the Company’s website www.pharmaequitygroup.com further information and all published announcements can be found. Inquiries regarding relations with investors and the stock market can be directed to: Thomas Kaas Selsø, CEO, Phone: +45 4022 2114 E-mail: investor@pharmaequitygroup.com. About Pharma Equity Group A/S Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthc